indapamide has been researched along with Diabetes Mellitus, Adult-Onset in 110 studies
Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.
indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the antihypertensive efficacy and safety of indapamide sustained-release (SR)/amlodipine compared with enalapril/amlodipine in patients 65 years and older with uncontrolled blood pressure (BP) on monotherapy, a post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria) was conducted." | 9.24 | Blood pressure-lowering efficacy of indapamide SR/amlodipine combination in older patients with hypertension: A post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria). ( Boully, C; Caillard, L; Chaussade, E; Hanon, O; Hernandorena, I, 2017) |
| "Hypertensive diabetic patients with microalbuminuria were included in this retrospective, post-hoc analysis of the Natrilix SR Versus Enalapril Study in Hypertensive Type 2 Diabetics With MicrOalbuminuRia (NESTOR) trial if they were uncontrolled on monotherapy (indapamide slow release (SR) 1." | 9.20 | Treatment of Hypertensive Patients With Diabetes and Microalbuminuria With Combination Indapamide SR/Amlodipine: Retrospective Analysis of NESTOR. ( Boully, C; Caillard, L; Chaussade, E; Cochiello, S; Hanon, O; Labourée, F, 2015) |
| "The objective of this study is to compare the effects of 2 types of diuretics, indapamide and hydrochlorothiazide, added to an angiotensin-converting enzyme inhibitor, on ventricular and arterial functions in patients with hypertension and diabetes." | 9.19 | The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: results of a randomized trial. ( Cinteza, M; Ciobanu, AO; Dragoi Galrinho, R; Dulgheru, R; Florescu, M; Granger, C; Magda, S; Vinereanu, D, 2014) |
| "To evaluate effects of 6-month therapy with losartan in combination with indapamide on a clinical course, immunological, metabolic parameters, left ventricular function, exercise tolerance and quality of life in patients with coronary heart disease (CHD) associated with metabolic syndrome (MS)." | 9.14 | [Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus]. ( Bolotskaia, LA; Derbeneva, NV; Frants, MV; Kuznetsova, AV; Lukinov, AV; Maianskaia, SD; Shilov, SN; Stepacheva, TA; Tepliakov, AT; Vdovina, TV, 2009) |
| "To assess real-life effectiveness of a perindopril/indapamide (Per/Ind) single-pill combination (SPC) in patients with hypertension (HT) and type 2 diabetes mellitus (T2DM), obesity and/or metabolic syndrome (MetS)." | 9.12 | Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies. ( Brzozowska-Villatte, R; De Champvallins, M; Dézsi, CA; Farsang, C; Glezer, M; Karpov, Y, 2021) |
| "9 years, 64% men) with type 2 diabetes, essential hypertension [systolic blood pressure (SBP) 140-180 mmHg, and diastolic blood pressure (DBP) < 110 mmHg], and persistent microalbuminuria (20-200 microg/min) were allocated randomly to groups to receive indapamide SR 1." | 9.11 | Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. ( Amouyel, P; Asmar, R; Fernandez, M; Finizola, B; Gallois, Y; Halabe, A; Hermansen, K; Ionescu-Tirgoviste, C; Jermendy, G; Kokot, F; Marre, M; Mion Júnior, D; Moyseev, V; Ollivier, JP; Opie, L; Puig, JG; Ruiz, M; Saldanha, MH; Scheen, A; Tuomilehto, J; Williams, B, 2004) |
| "To examine the factors that determine the blood pressure response to enalapril and nifedipine monotherapy in the treatment of hypertension associated with non-insulin-dependent diabetes mellitus (NIDDM)." | 9.08 | Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. ( Chan, JC; Cheung, CK; Cockram, CS; Law, LK; Nicholls, MG; Swaminathan, R, 1995) |
| "Indapamide can cause both severe hypokalemia and hyponatremia." | 7.69 | Indapamide-induced severe hyponatremia and hypokalemia. ( Chan, TY, 1995) |
| " Perindopril/indapamide dosage could be increased, from 5/1." | 6.79 | Efficacy of single-pill perindopril/indapamide in patients with hypertension and type 2 diabetes. ( Gorbat, TV; Netchessova, TA; Shepelkevich, AP, 2014) |
| "Perindopril/indapamide treatment resulted in a statistically significant higher fall in both BP (-3." | 6.71 | Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. ( De Leeuw, PW; Erdogan, G; Halimi, S; Hamani, A; Hess, B; Jermendy, G; Luger, A; Mechmeche, R; Mogensen, CE; Nolan, J; Ribeiro, A; Ritz, E; Ruilope, L; Rull, J; Sanchez, R; Sareli, P; Scheen, A; Sirotiakova, J; Taton, J; Thomas, SM; Viberti, G; Widimsky, J, 2003) |
| "Hyponatremia is the most frequently encountered electrolyte abnormality among hospitalized patients and thiazide users." | 5.39 | Prevalence of hyponatremia among patients who used indapamide and hydrochlorothiazide: a single center retrospective study. ( Abukhalid, N; Al Ammari, M; Al Johani, N; Al Qahtani, M; Al Sayyari, A; Al Swaidan, L; Alshahrani, A; Alskaini, A; Binsalih, S; Theaby, A, 2013) |
| "In hypertensive patients with Type 2 diabetes, a greater reduction of urinary albumin excretion can be obtained with the perindopril/indapamide association compared with an angiotensin-converting enzyme inhibitor administered as monotherapy." | 5.33 | What can be learned from the experience with the fixed low-dose combination of perindopril/indapamide in the treatment of hypertension? ( Waeber, B, 2005) |
| "To examine the antihypertensive efficacy and safety of indapamide sustained-release (SR)/amlodipine compared with enalapril/amlodipine in patients 65 years and older with uncontrolled blood pressure (BP) on monotherapy, a post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria) was conducted." | 5.24 | Blood pressure-lowering efficacy of indapamide SR/amlodipine combination in older patients with hypertension: A post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria). ( Boully, C; Caillard, L; Chaussade, E; Hanon, O; Hernandorena, I, 2017) |
| "Hypertensive diabetic patients with microalbuminuria were included in this retrospective, post-hoc analysis of the Natrilix SR Versus Enalapril Study in Hypertensive Type 2 Diabetics With MicrOalbuminuRia (NESTOR) trial if they were uncontrolled on monotherapy (indapamide slow release (SR) 1." | 5.20 | Treatment of Hypertensive Patients With Diabetes and Microalbuminuria With Combination Indapamide SR/Amlodipine: Retrospective Analysis of NESTOR. ( Boully, C; Caillard, L; Chaussade, E; Cochiello, S; Hanon, O; Labourée, F, 2015) |
| "To evaluate the impact of a 12-week combined antihypertensive therapy with enalapril + indapamide on endothelial dysfunction in patients with arterial hypertension (AH) and diabetes mellitus (DM) type 2." | 5.20 | [Possibilities of Correction of Endothelial Dysfunction at the Background of Combined Antihypertensive Therapy in Patients With Arterial Hypertension and Type 2 Diabetes]. ( Derevianchenko, MV; Statsenko, ME, 2015) |
| "The objective of this study is to compare the effects of 2 types of diuretics, indapamide and hydrochlorothiazide, added to an angiotensin-converting enzyme inhibitor, on ventricular and arterial functions in patients with hypertension and diabetes." | 5.19 | The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: results of a randomized trial. ( Cinteza, M; Ciobanu, AO; Dragoi Galrinho, R; Dulgheru, R; Florescu, M; Granger, C; Magda, S; Vinereanu, D, 2014) |
| "The aim of the study was to assess effect of 12-week long combined therapy with quinapril (accupro), an ACE inhibitor, and diuretic indapamide SR on arterial pressure (AP), carbohydrate and lipid metabolism, and safety of the treatment in patients having arterial hypertension (AH) with and without DM2." | 5.14 | [Combined antihypertensive therapy in patients with arterial hypertension and type 2 diabetes]. ( Bondareva, IN; Nesterov, IuI; Poltavtseva, OV; Tepliakov, AT, 2009) |
| "To investigate antihypertensive efficacy, effects on endothelial, diastolic function of the left ventricle and metabolism of combination of ACE inhibitor quinapril (accupro) with diuretic indapamide SR in patients with hypertension of the second-third degree and type 2 diabetes mellitus (DM) and free of DM." | 5.14 | [Combined antihypertensive treatment of patients with hypertension and type 2 diabetes mellitus]. ( Bondareva, IN; Nesterov, IuI; Poltavtseva, OV; Tepliakov, AT, 2009) |
| "The aim of this work was to investigate influence of indapamide and perindopril on blood pressure and metabolism at patients with type 2 diabetes and new diagnosed arterial hypertension." | 5.14 | [Hypotensive and metabolic effect of indapamide and perindopril in patients with type 2 diabetes and arterial hypertensia]. ( Askerov, MM, 2009) |
| "To evaluate effects of 6-month therapy with losartan in combination with indapamide on a clinical course, immunological, metabolic parameters, left ventricular function, exercise tolerance and quality of life in patients with coronary heart disease (CHD) associated with metabolic syndrome (MS)." | 5.14 | [Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus]. ( Bolotskaia, LA; Derbeneva, NV; Frants, MV; Kuznetsova, AV; Lukinov, AV; Maianskaia, SD; Shilov, SN; Stepacheva, TA; Tepliakov, AT; Vdovina, TV, 2009) |
| "The study demonstrates the value of including the thiazide-like diuretic indapamide SR in a combined antihypertensive regimen to control BP in hypertensive patients with added cardiovascular risk factors whose hypertension is difficult to treat." | 5.14 | Treating hypertension by rational use of diuretics: results of the Russian ARGUS-2 Study. ( Kobalava, ZD; Kotovskaya, YV; Moiseev, VS; Villevalde, SV, 2009) |
| "To assess real-life effectiveness of a perindopril/indapamide (Per/Ind) single-pill combination (SPC) in patients with hypertension (HT) and type 2 diabetes mellitus (T2DM), obesity and/or metabolic syndrome (MetS)." | 5.12 | Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies. ( Brzozowska-Villatte, R; De Champvallins, M; Dézsi, CA; Farsang, C; Glezer, M; Karpov, Y, 2021) |
| "Indapamide SR is not less effective than enalapril in reducing microalbuminuria and blood pressure in patients aged >65 years of age with type 2 diabetes and hypertension." | 5.12 | Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. ( Amouyel, P; Asmar, R; Fernandez, M; Finizola, B; Gallois, Y; Halabe, A; Hermansen, K; Ionescu-Tirgoviste, C; Jermendy, G; Kokot, F; Marre, M; Mion, D; Moyseev, V; Ollivier, JP; Opie, L; Puig, JG; Ruiz, M; Saldanha, MH; Scheen, A; Tuomilehto, J; Williams, B, 2007) |
| "9 years, 64% men) with type 2 diabetes, essential hypertension [systolic blood pressure (SBP) 140-180 mmHg, and diastolic blood pressure (DBP) < 110 mmHg], and persistent microalbuminuria (20-200 microg/min) were allocated randomly to groups to receive indapamide SR 1." | 5.11 | Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. ( Amouyel, P; Asmar, R; Fernandez, M; Finizola, B; Gallois, Y; Halabe, A; Hermansen, K; Ionescu-Tirgoviste, C; Jermendy, G; Kokot, F; Marre, M; Mion Júnior, D; Moyseev, V; Ollivier, JP; Opie, L; Puig, JG; Ruiz, M; Saldanha, MH; Scheen, A; Tuomilehto, J; Williams, B, 2004) |
| "To evaluate the effect of the sustained-release formulation of indapamide (indapamide SR) in type 2 diabetic patients with mild-to-moderate hypertension and its possible side effects, particularly on glucose metabolism and lipid profiles." | 5.10 | Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. ( He, CT; Hsieh, AT; Hsieh, CH; Hung, YJ; Kuo, SW; Lian, WC; Wu, LY; Yang, TC, 2003) |
| "We conducted a prospective, randomized, open-label, blinded endpoint crossover study comparing the metabolic responses to the addition of either hydrochlorothiazide (HCTZ) or indapamide, in 18 diabetic hypertensive patients receiving ACE inhibitor monotherapy for hypertension." | 5.10 | Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy. ( Gilbert, RE; Krum, H; Skiba, M, 2003) |
| "The first fundamental study devoted to the reduction of microalbuminuria with a antihypertensive diuretic (indapamide SR) in type 2 diabetes with hypertension, the Marre study (NESTOR) was designed to demonstrate that this antihypertension agent could be an interesting therapeutic alternative by comparing its efficacy on microalbuminuria with that of enalapril 10 mg during a treatment period of 52 weeks." | 5.10 | [Treatment of hypertensive type 2 diabetes patients with microalbuminuria]. ( Marre, M, 2002) |
| "To examine the factors that determine the blood pressure response to enalapril and nifedipine monotherapy in the treatment of hypertension associated with non-insulin-dependent diabetes mellitus (NIDDM)." | 5.08 | Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. ( Chan, JC; Cheung, CK; Cockram, CS; Law, LK; Nicholls, MG; Swaminathan, R, 1995) |
| "We conducted an analysis of the action in diabetes and vascular disease: preterax and diamicron-MR controlled evaluation ADVANCE and perindopril protection against recurrent stroke study PROGRESS trials, including 14 684 participants allocated combination therapy or placebo." | 3.85 | Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the PROGRESS and ADVANCE trials. ( Atkins, ER; Chalmers, J; Cooper, M; Hamet, P; Harrap, S; Hirakawa, Y; Lees, K; Liu, L; Mancia, G; Marre, M; Perkovic, V; Poulter, N; Rodgers, A; Salam, A; Williams, B; Woodward, M, 2017) |
| " While randomized trials have demonstrated that blood pressure lowering reduces vascular complications in subjects with type 2 diabetes and hypertension, ADVANCE was designed to determine whether the addition of a fixed combination of perindopril and indapamide, on top of comprehensive and effective cardiovascular treatments and glucose control therapy, would produce further benefits, irrespective of the initial blood pressure." | 3.74 | Advances in reducing the burden of vascular disease in type 2 diabetes. ( Chalmers, J; Joshi, R; Patel, A, 2008) |
| "Indapamide can cause both severe hypokalemia and hyponatremia." | 3.69 | Indapamide-induced severe hyponatremia and hypokalemia. ( Chan, TY, 1995) |
| "Weight loss is strongly recommended for overweight and obese adults with type 2 diabetes." | 2.94 | The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. ( Chalmers, J; Hamet, P; Harrap, S; Lee, AK; Marre, M; Mcevoy, JW; Ohkuma, T; Selvin, E; Sharrett, AR; Wang, D; Warren, B; Williams, B; Woodward, M, 2020) |
| "We analyzed 10,624 patients with type 2 diabetes free from baseline major PAD in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) clinical trial." | 2.82 | Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes. ( Chalmers, J; Harrap, S; Hirakawa, Y; Lisheng, L; Mancia, G; Marre, M; Mohammedi, K; Neal, B; Rodgers, A; Williams, B; Woodward, M; Zoungas, S, 2016) |
| "A total of 11 140 patients with type 2 diabetes mellitus were randomly assigned to fixed combination of perindopril-indapamide (4/1." | 2.79 | Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. ( Arima, H; Chalmers, J; Harrap, S; Hirakawa, Y; Mancia, G; Patel, A; Poulter, N; Williams, B; Woodward, M; Zoungas, S, 2014) |
| " Perindopril/indapamide dosage could be increased, from 5/1." | 2.79 | Efficacy of single-pill perindopril/indapamide in patients with hypertension and type 2 diabetes. ( Gorbat, TV; Netchessova, TA; Shepelkevich, AP, 2014) |
| "In patients with type 2 diabetes, moderate alcohol use, particularly wine consumption, is associated with reduced risks of cardiovascular events and all-cause mortality." | 2.79 | The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes. ( Blomster, JI; Chalmers, J; Chow, CK; Harrap, S; Hillis, GS; Li, Q; Mancia, G; Neal, B; Patel, A; Poulter, N; Williams, B; Woodward, M; Zoungas, S, 2014) |
| "Low HDL-C is associated with cancer risk in patients with type II diabetes." | 2.78 | The association of high-density lipoprotein cholesterol with cancer incidence in type II diabetes: a case of reverse causality? ( Chalmers, J; Cooper, ME; Mancia, G; Marre, M; Morton, J; Ng, MK; Poulter, NR; Woodward, M; Zoungas, S, 2013) |
| "11,140 participants with type 2 diabetes, from the ADVANCE trial, were randomized to perindopril-indapamide or matching placebo." | 2.77 | Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes. ( Beulens, JW; Chalmers, J; Cooper, ME; Grobbee, DE; Harrap, S; Kengne, AP; Mancia, G; Neal, B; Patel, A; Poulter, N; van der Schouw, YT; van Dieren, S; Woodward, M; Zoungas, S, 2012) |
| "Patients with type 2 diabetes were randomized to perindopril-indapamide (4 mg/1." | 2.75 | Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. ( Cass, A; Chalmers, J; Cooper, M; Grobbee, DE; Heerspink, HJ; Mancia, G; Mogensen, CE; Neal, B; Ninomiya, T; Perkovic, V; Woodward, M; Zoungas, S, 2010) |
| "The increase in type 2 diabetes mellitus is associated to cardiovascular morbidity and mortality." | 2.75 | Management of high blood pressure in type 2 diabetes: perindopril/indapamide fixed-dose combination and the ADVANCE trial [corrected]. ( Ghiadoni, L, 2010) |
| "In this cohort of men with type 2 diabetes, ED was associated with a range of CVD events." | 2.75 | Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial. ( Batty, GD; Chalmers, J; Czernichow, S; de Galan, BE; Hamet, P; Harrap, SB; Huxley, R; Li, Q; Neal, B; Patel, A; Poulter, N; Woodward, M; Zoungas, S, 2010) |
| "Thus, in patients with type 2 diabetes, a drug regimen based on a fixed-dose combination of perindopril/ indapamide affords major protection against both the macro and microvascular complications." | 2.73 | [ADVANCE: a morbidity mortality study of diabetes and hypertension]. ( Feihl, F; Heim, A; Waeber, B, 2008) |
| "A total of 11140 individuals with type 2 diabetes were randomly assigned to fixed combination perindopril-indapamide or matching placebo, after a 6-week run-in period." | 2.73 | Blood pressure lowering with fixed combination perindopril-indapamide: key findings from ADVANCE. ( Chalmers, J; Joshi, R; Kengne, AP; MacMahon, S, 2008) |
| "Perindopril/indapamide treatment resulted in a statistically significant higher fall in both BP (-3." | 2.71 | Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. ( De Leeuw, PW; Erdogan, G; Halimi, S; Hamani, A; Hess, B; Jermendy, G; Luger, A; Mechmeche, R; Mogensen, CE; Nolan, J; Ribeiro, A; Ritz, E; Ruilope, L; Rull, J; Sanchez, R; Sareli, P; Scheen, A; Sirotiakova, J; Taton, J; Thomas, SM; Viberti, G; Widimsky, J, 2003) |
| "Patients with type 2 diabetes mellitus have markedly increased risks of developing vascular diseases." | 2.71 | [ADVANCE study: objectives, design and current status]. ( Chalmers, J, 2003) |
| "CARDIOVASCULAR RISK OF LEFT VENTRICULAR HYPERTROPHY: Because of the rhythmic, mechanical and ischemic risk related to it, the left ventricular hypertrophy (LVH) is considered to be a major independent risk factor for cardiovascular disease which should be screened for and treated early." | 2.70 | [Management of hypertensive patients with left ventricular hypertrophy]. ( Ambrosioni, E, 2002) |
| "Perindopril/indapamide treatment has been shown to reduce blood pressure and to have significant beneficial effects on arterial distensibility, kidney structure and function, and endothelial function." | 2.58 | Vascular legacy beyond blood pressure control: benefits of perindopril/indapamide combination in hypertensive patients with diabetes. ( Lévy, BI; Taddei, S, 2018) |
| " The results can be related to gradually weakening protective effect of perindopril/indapamide combination on cardiovascular system, and are indicative of the expedience of long-term use of this antihypertensive therapy for maximal lowering of mortality of patients with diabetes." | 2.52 | [ADVANCE-ON Trial; How to Achieve Maximum Reduction of Mortality in Patients With Type 2 Diabetes]. ( Kanorskiĭ, SG, 2015) |
| "Patients with type 2 diabetes mellitus exhibit a marked increase in cardiovascular and renal risk." | 2.45 | The ADVANCE trial: clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus. ( de la Sierra, A; Ruilope, LM; Waeber, B, 2009) |
| " Indapamide, a thiazide-type diuretic, was available for many years at a dosage of 2." | 2.43 | An overview of the pharmacology and clinical efficacy of indapamide sustained release. ( Bataillard, A; McIntyre, H; Sassard, J, 2005) |
| "Pharmacological treatment of hypertension represents a cost-effective way of preventing cardiovascular and renal complications." | 2.43 | Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials. ( Waeber, B, 2006) |
| "The treatment with indapamide SR resulted in a better or equivalent control of SBP than treatment with a standard dose of a true thiazide diuretic (hydrochlorothiazide), a calcium channel blocker (amlodipine), and an angiotensin-converting enzyme inhibitor (enalapril)." | 2.42 | Efficacy of indapamide 1.5 mg, sustained release, in the lowering of systolic blood pressure. ( London, GM, 2004) |
| " The estimated individual effects can inform treatment decisions once individual weights assigned to positive and adverse effects have been specified." | 1.43 | Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. ( Chalmers, J; Grobbee, DE; Harrap, S; Heller, S; Mancia, G; Marre, M; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S, 2016) |
| "Hypertension and type 2 diabetes mellitus (T2DM) synergistically deteriorate the vascular environment, making blood pressure reduction challenging, and substantially increasing cardiovascular risk." | 1.40 | Efficacy and tolerability of fixed-dose combination of perindopril/indapamide in type 2 diabetes mellitus: PICASSO trial. ( Farsang, C, 2014) |
| "Hyponatremia is the most frequently encountered electrolyte abnormality among hospitalized patients and thiazide users." | 1.39 | Prevalence of hyponatremia among patients who used indapamide and hydrochlorothiazide: a single center retrospective study. ( Abukhalid, N; Al Ammari, M; Al Johani, N; Al Qahtani, M; Al Sayyari, A; Al Swaidan, L; Alshahrani, A; Alskaini, A; Binsalih, S; Theaby, A, 2013) |
| "In hypertensive patients with Type 2 diabetes, a greater reduction of urinary albumin excretion can be obtained with the perindopril/indapamide association compared with an angiotensin-converting enzyme inhibitor administered as monotherapy." | 1.33 | What can be learned from the experience with the fixed low-dose combination of perindopril/indapamide in the treatment of hypertension? ( Waeber, B, 2005) |
| "Factors that must be considered for the treatment of hypertension in patients, particularly with type 2 diabetes." | 1.31 | [Reflexion of French experts on the key points of the symposium]. ( Dubourg, O; Forette, F; Hanon, O; Mallion, JM; Marre, M, 2002) |
| "Indapamide is a nonthiazide antihypertensive agent that appears to respect the glucose tolerance in hypertensive patients." | 1.27 | Antihypertensive therapy in diabetic patients. The use of indapamide. ( Harrower, AD; McFarlane, G, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (2.73) | 18.7374 |
| 1990's | 4 (3.64) | 18.2507 |
| 2000's | 50 (45.45) | 29.6817 |
| 2010's | 47 (42.73) | 24.3611 |
| 2020's | 6 (5.45) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, AK | 1 |
| Woodward, M | 32 |
| Wang, D | 3 |
| Ohkuma, T | 4 |
| Warren, B | 1 |
| Sharrett, AR | 1 |
| Williams, B | 19 |
| Marre, M | 25 |
| Hamet, P | 20 |
| Harrap, S | 21 |
| Mcevoy, JW | 3 |
| Chalmers, J | 39 |
| Selvin, E | 4 |
| Knudsen, ST | 1 |
| Cooper, ME | 9 |
| Tian, J | 1 |
| Cooper, M | 10 |
| Mancia, G | 23 |
| Poulter, N | 21 |
| Wang, JG | 2 |
| Zoungas, S | 24 |
| Kim, H | 1 |
| Jun, M | 2 |
| Poulter, NR | 3 |
| Rebholz, CM | 1 |
| Farsang, C | 2 |
| Dézsi, CA | 1 |
| Brzozowska-Villatte, R | 1 |
| De Champvallins, M | 1 |
| Glezer, M | 1 |
| Karpov, Y | 1 |
| Rosolová, H | 1 |
| Hanon, O | 3 |
| Caillard, L | 2 |
| Chaussade, E | 2 |
| Hernandorena, I | 1 |
| Boully, C | 2 |
| Mohammedi, K | 4 |
| Colagiuri, S | 5 |
| Lévy, BI | 1 |
| Taddei, S | 1 |
| van Steen, SC | 1 |
| Li, Q | 7 |
| Grobbee, DE | 11 |
| DeVries, JH | 1 |
| Herrington, W | 1 |
| Rodgers, A | 9 |
| Perkovic, V | 12 |
| Coresh, J | 1 |
| Glasziou, P | 6 |
| Neal, B | 16 |
| Rahman, F | 1 |
| Muntner, P | 1 |
| Juraschek, SP | 1 |
| Lazo, M | 1 |
| van der Merwe, WM | 1 |
| Sobngwi, E | 1 |
| Mfeukeu-Kuate, L | 1 |
| Kouam, M | 1 |
| Tankeu, AT | 1 |
| Nganou-Gnindjio, CN | 1 |
| Hamadou, B | 1 |
| Etoa, M | 1 |
| Ngassam, E | 1 |
| Nkamgna, A | 1 |
| Dehayem, MY | 1 |
| Kaze, FF | 1 |
| Kengne, AP | 9 |
| Mbanya, JC | 1 |
| Al Qahtani, M | 1 |
| Alshahrani, A | 1 |
| Alskaini, A | 1 |
| Abukhalid, N | 1 |
| Al Johani, N | 1 |
| Al Ammari, M | 1 |
| Al Swaidan, L | 1 |
| Binsalih, S | 1 |
| Al Sayyari, A | 1 |
| Theaby, A | 1 |
| Morton, J | 1 |
| Ng, MK | 1 |
| Konig, M | 1 |
| Lamos, EM | 1 |
| Stein, SA | 1 |
| Davis, SN | 1 |
| Bischoff, A | 1 |
| Arima, H | 3 |
| Hirakawa, Y | 6 |
| Patel, A | 21 |
| Yamout, H | 1 |
| Bakris, GL | 3 |
| Netchessova, TA | 1 |
| Shepelkevich, AP | 1 |
| Gorbat, TV | 1 |
| Blomster, JI | 1 |
| Chow, CK | 1 |
| Hillis, GS | 1 |
| Ninomiya, T | 6 |
| Billot, L | 3 |
| Monaghan, H | 1 |
| Joshi, R | 7 |
| Grobbee, D | 3 |
| Heller, S | 8 |
| Lisheng, L | 4 |
| Matthews, DR | 2 |
| Mogensen, CE | 6 |
| MacMahon, S | 9 |
| Vinereanu, D | 1 |
| Dulgheru, R | 1 |
| Magda, S | 1 |
| Dragoi Galrinho, R | 1 |
| Florescu, M | 1 |
| Cinteza, M | 1 |
| Granger, C | 1 |
| Ciobanu, AO | 1 |
| van der Leeuw, J | 2 |
| Visseren, FL | 2 |
| van der Graaf, Y | 2 |
| Zhang, Y | 1 |
| Agnoletti, D | 1 |
| Xu, Y | 1 |
| Safar, ME | 1 |
| Labourée, F | 1 |
| Cochiello, S | 1 |
| Kanorskiĭ, SG | 1 |
| Statsenko, ME | 1 |
| Derevianchenko, MV | 1 |
| Grobbee, R | 1 |
| Jardine, M | 1 |
| Wong, MG | 1 |
| Matthews, D | 1 |
| Ostroumova, OD | 1 |
| Zykova, AA | 1 |
| Karpov, YA | 1 |
| Atkins, ER | 1 |
| Salam, A | 1 |
| Lees, K | 1 |
| Liu, L | 3 |
| Tropeano, AI | 1 |
| Katsahian, S | 1 |
| Molle, D | 1 |
| Grimaldi, A | 1 |
| Laurent, S | 2 |
| de Galan, BE | 4 |
| Pillai, A | 3 |
| Cass, A | 4 |
| Nesterov, IuI | 2 |
| Bondareva, IN | 2 |
| Tepliakov, AT | 3 |
| Poltavtseva, OV | 2 |
| Zannad, F | 1 |
| Bi, Y | 1 |
| Bompoint, S | 2 |
| Askerov, MM | 1 |
| Maianskaia, SD | 1 |
| Bolotskaia, LA | 1 |
| Vdovina, TV | 1 |
| Stepacheva, TA | 1 |
| Kuznetsova, AV | 1 |
| Lukinov, AV | 1 |
| Derbeneva, NV | 1 |
| Frants, MV | 1 |
| Shilov, SN | 1 |
| Kobalava, ZD | 1 |
| Kotovskaya, YV | 1 |
| Villevalde, SV | 1 |
| Moiseev, VS | 1 |
| Beulens, JW | 2 |
| Vingerling, JR | 1 |
| Cruickshank, JK | 1 |
| Hughes, AD | 1 |
| Stanton, A | 1 |
| Lu, J | 1 |
| McG Thom, SA | 1 |
| Stolk, RP | 1 |
| Travert, F | 3 |
| Anderson, C | 1 |
| Dufouil, C | 1 |
| Hackett, M | 1 |
| Heller, SR | 1 |
| Pan, CY | 3 |
| Waeber, B | 4 |
| de la Sierra, A | 1 |
| Ruilope, LM | 2 |
| Heerspink, HJ | 1 |
| Ghiadoni, L | 1 |
| Batty, GD | 1 |
| Czernichow, S | 1 |
| Huxley, R | 1 |
| Harrap, SB | 1 |
| Lievre, M | 1 |
| Koya, D | 1 |
| Pan, C | 1 |
| Januszewicz, A | 1 |
| Tandon, N | 1 |
| Joshi, P | 1 |
| Nedogoda, SV | 1 |
| van Dieren, S | 1 |
| van der Schouw, YT | 1 |
| Ambrosioni, E | 1 |
| Kaplan, NM | 2 |
| Mallion, JM | 1 |
| Forette, F | 1 |
| Dubourg, O | 1 |
| Toblli, JE | 1 |
| DeRosa, G | 1 |
| Rivas, C | 1 |
| Cao, G | 1 |
| Piorno, P | 1 |
| Pagano, P | 1 |
| Forcada, P | 1 |
| Viberti, G | 1 |
| Halimi, S | 1 |
| Ritz, E | 1 |
| Ruilope, L | 1 |
| Jermendy, G | 4 |
| Widimsky, J | 1 |
| Sareli, P | 1 |
| Taton, J | 1 |
| Rull, J | 1 |
| Erdogan, G | 1 |
| De Leeuw, PW | 1 |
| Ribeiro, A | 1 |
| Sanchez, R | 1 |
| Mechmeche, R | 1 |
| Nolan, J | 1 |
| Sirotiakova, J | 1 |
| Hamani, A | 1 |
| Scheen, A | 4 |
| Hess, B | 1 |
| Luger, A | 1 |
| Thomas, SM | 1 |
| Garcia Puig, J | 1 |
| Kokot, F | 3 |
| Fernandez, M | 3 |
| Opie, L | 3 |
| Moyseev, V | 3 |
| Ionescu-Tirgoviste, C | 3 |
| Saldanha, MH | 3 |
| Halabe, A | 3 |
| Mion, D | 2 |
| Ruiz, M | 3 |
| Hermansen, K | 3 |
| Tuomilehto, J | 3 |
| Finizola, B | 3 |
| Pozza, G | 1 |
| Chastang, C | 1 |
| Ollivier, JP | 3 |
| Amouyel, P | 3 |
| Asmar, R | 3 |
| Kuo, SW | 1 |
| Hung, YJ | 1 |
| Hsieh, AT | 1 |
| Wu, LY | 1 |
| Hsieh, CH | 1 |
| He, CT | 1 |
| Yang, TC | 1 |
| Lian, WC | 1 |
| Krum, H | 1 |
| Skiba, M | 1 |
| Gilbert, RE | 1 |
| Puig, JG | 2 |
| Mion Júnior, D | 1 |
| Gallois, Y | 2 |
| London, GM | 1 |
| Sassard, J | 1 |
| Bataillard, A | 1 |
| McIntyre, H | 1 |
| Segura, J | 1 |
| Czupryniak, L | 1 |
| Pawłowski, M | 1 |
| Saryusz-Wolska, M | 1 |
| Loba, J | 1 |
| Liu, LS | 1 |
| Einecke, D | 1 |
| Duka, I | 1 |
| Scheen, AJ | 1 |
| Krzesinski, JM | 1 |
| Nagy, V | 1 |
| Dunstan, E | 1 |
| Heim, A | 1 |
| Feihl, F | 1 |
| Berkwits, M | 1 |
| Hönl, SB | 1 |
| Harrower, AD | 2 |
| McFarlane, G | 2 |
| Donnelly, T | 1 |
| Gray, CE | 1 |
| Flack, JR | 1 |
| Molyneaux, L | 1 |
| Willey, K | 1 |
| Yue, DK | 1 |
| Chan, JC | 1 |
| Nicholls, MG | 1 |
| Cheung, CK | 1 |
| Law, LK | 1 |
| Swaminathan, R | 1 |
| Cockram, CS | 1 |
| Chan, TY | 1 |
| Gambardella, S | 1 |
| Frontoni, S | 1 |
| Lala, A | 1 |
| Felici, MG | 1 |
| Spallone, V | 1 |
| Scoppola, A | 1 |
| Jacoangeli, F | 1 |
| Menzinger, G | 1 |
| Byam, N | 1 |
| Patrick, AL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925] | Phase 3 | 11,140 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Evaluation of the HeartWare Left Ventricular Assist Device for the Treatment of Advanced Heart Failure[NCT00751972] | 140 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide on Blood Pressure Control in Newly Diagnosed Type 2 Diabetes Individuals With Hypertension[NCT03747978] | Phase 4 | 30 participants (Actual) | Interventional | 2016-10-01 | Completed | ||
| Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
| Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study[NCT00949286] | 8,494 participants (Actual) | Observational | 2010-01-31 | Completed | |||
| Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in Newly Diagnosed and Uncontrolled Hypertensive Patients[NCT03738761] | Phase 4 | 471 participants (Actual) | Interventional | 2018-02-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The 6MWT is a simple test which does not require expensive equipment or advanced training for technicians. The test involves asking the patient to walk the longest distance possible in a set interval of 6 min, through a walking course (corridor) preferably 30-m long. The patient can stop or slow down at any time and then resume walking, depending on his/her degree of fatigue.~A longer distance walked is indicative of a better outcome." (NCT00751972)
Timeframe: Baseline and 180 Days
| Intervention | meters (Mean) |
|---|---|
| HeartWare® VAS | 150.14 |
"The EQ-5D is a standardized instrument for use as a generic measure of the quality of health-related life and of health outcome.~The EuroQoL EQ-5D is a descriptive system of health-related quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.~Scores are transformed to a range of 0-100, in which higher scores reflect better health status." (NCT00751972)
Timeframe: Baseline and 180 Days
| Intervention | units on a EuroQol EQ-5D scale (Mean) |
|---|---|
| HeartWare® VAS | 29.53 |
"KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life for patients with congestive heart failure. It is a predictive tool that tracks how patients are doing if they have weakened heart muscle due to prior heart attacks, heart valve problems, viral infections, or other causes.~The KCCQ's questions are used to calculate scores in ten domains:~Physical Limitation, Symptom Stability, Frequency, Burden and Total Symptom. Social Limitation, Self-Efficacy, Quality of Life, and Clinical Summary. Overall Summary: a combined measure of all the above~For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Scores are transformed to a range of 0-100, in which higher scores reflect better health status." (NCT00751972)
Timeframe: Baseline and 180 Days
| Intervention | units on a KCCQ scale (Mean) |
|---|---|
| HeartWare® VAS | 30.94 |
All subjects will be followed for date of death until 180 days. (NCT00751972)
Timeframe: 180 Days
| Intervention | Percentage of participants with survival (Number) |
|---|---|
| HeartWare® VAS | 94.3 |
| Contemporaneous Control | 91.2 |
The primary endpoint is success at 180 days which is defined as alive on the originally implanted HeartWare® LVAD or transplanted or explanted for recovery. A patient must survive 60 days post-explant for recovery to be considered successful. (NCT00751972)
Timeframe: 180 days
| Intervention | Percentage of participants with success (Number) |
|---|---|
| HeartWare® VAS | 90.7 |
| Contemporaneous Control | 90.1 |
Adverse events are only provided for patients who received a HeartWare Ventricular Assist Device (HeartWare® VAS). Adverse events as described by INTERMACS for the contemporaneous control population were not a part of the agreement for analysis and thus not provided by INTERMACS, and so not included in the Adverse Event Module and relevant Outcome Measures for comparison. (NCT00751972)
Timeframe: 180 Days
| Intervention | percentage of patients (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bleeding requiring reoperation | Infections - Local | Infections - Driveline | Infections - Sepsis | Neurologic Event-Ischemic Cerebrovascular accident | Neurologic Event-Hemorrhagic CVA | Neurologic Event - Transient Ischemic Attack(TIA)A | Right Heart Failure - requiring Inotropes | Right Heart Failure - requiring RVAD | Respiratory Dysfunction | Arterial Thromboembolism | Venous Thromboembolism | Renal Dysfunction | Hepatic Dysfunction | Hemolysis | |
| HeartWare® VAS | 17.1 | 25.0 | 12.1 | 11.4 | 7.1 | 4.3 | 4.3 | 16.0 | 2.9 | 19.3 | 2.9 | 6.4 | 5.7 | 2.9 | 3.6 |
The INTERMACS event device malfunction defined a failure of the HeartWare VAS as either pump failure or non-pump failure. (NCT00751972)
Timeframe: 180 Days
| Intervention | Number of events (Number) | |
|---|---|---|
| Pump Failure (exchange) | Non pump failure | |
| HeartWare® VAS | 7 | 19 |
16 reviews available for indapamide and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Humans; Hypertension; Hypoglycemic Agents; Indap | 2020 |
Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Drug Combinations; Humans; | 2021 |
Vascular legacy beyond blood pressure control: benefits of perindopril/indapamide combination in hypertensive patients with diabetes.
Topics: Antihypertensive Agents; Blood Circulation; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hy | 2018 |
An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Typ | 2013 |
[ADVANCE-ON Trial; How to Achieve Maximum Reduction of Mortality in Patients With Type 2 Diabetes].
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Huma | 2015 |
Implications of the ADVANCE study for clinical practice.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypertension; | 2008 |
Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Evidence-Based Medici | 2008 |
The ADVANCE trial: clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus | 2009 |
What matters in ADVANCE and ADVANCE-ON.
Topics: Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabete | 2012 |
Very-low-dose combination of perindopril and indapamide: efficacy on blood pressure and target-organ damage.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus | 2003 |
Efficacy of indapamide 1.5 mg, sustained release, in the lowering of systolic blood pressure.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Delayed-Action Preparations; Diabetes Me | 2004 |
An overview of the pharmacology and clinical efficacy of indapamide sustained release.
Topics: Albuminuria; Antihypertensive Agents; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Eviden | 2005 |
Renal protection in diabetic patients: benefits of a first-line combination of perindopril-indapamide (Preterax).
Topics: Albuminuria; Antihypertensive Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic | 2006 |
Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
New insights from ADVANCE.
Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Complications; Diabetes Mellitus, T | 2007 |
[The prevention of the hypertension related damage in type-2 diabetes: the first step of the ADVANCE trial].
Topics: Antihypertensive Agents; Blood Pressure; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Com | 2008 |
62 trials available for indapamide and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.
Topics: Adult; Aged; Body-Weight Trajectory; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combin | 2020 |
Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2 | 2020 |
Alternative kidney filtration markers and the risk of major macrovascular and microvascular events, and all-cause mortality in individuals with type 2 diabetes in the ADVANCE trial.
Topics: Aged; Antihypertensive Agents; beta 2-Microglobulin; Biomarkers; Cause of Death; Creatinine; Cystati | 2020 |
Blood pressure-lowering efficacy of indapamide SR/amlodipine combination in older patients with hypertension: A post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria).
Topics: Aged; Aged, 80 and over; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes | 2017 |
Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
Topics: Aged; Antihypertensive Agents; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Combinations; | 2018 |
Associations between body mass index and the risk of renal events in patients with type 2 diabetes.
Topics: Aged; Albuminuria; Blood Glucose; Body Mass Index; Creatinine; Diabetes Mellitus, Type 2; Drug Combi | 2018 |
Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cardiovascular Diseases; Creatinine; Diabe | 2019 |
Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes | 2019 |
Response of 1,5-anhydroglucitol level to intensive glucose- and blood-pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Deoxyglucose; Diabetes Mellitus, Type 2; Drug Therapy, | 2019 |
Short-term effects of perindopril-amlodipine vs perindopril-indapamide on blood pressure control in sub-Saharan type 2 diabetic individuals newly diagnosed for hypertension: A double-blinded randomized controlled trial.
Topics: Africa South of the Sahara; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Moni | 2019 |
The association of high-density lipoprotein cholesterol with cancer incidence in type II diabetes: a case of reverse causality?
Topics: Australia; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Indapamide; Male; | 2013 |
Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, T | 2014 |
Efficacy of single-pill perindopril/indapamide in patients with hypertension and type 2 diabetes.
Topics: Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Comorbidity; Diabetes Mellitus, Type 2; | 2014 |
The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes.
Topics: Aged; Alcohol Drinking; Antihypertensive Agents; Coronary Disease; Diabetes Mellitus, Type 2; Diabet | 2014 |
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Topics: Aged; Aged, 80 and over; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2014 |
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Topics: Aged; Aged, 80 and over; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2014 |
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Topics: Aged; Aged, 80 and over; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2014 |
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Topics: Aged; Aged, 80 and over; Blood Glucose; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2014 |
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
Topics: Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Female; Follow | 2014 |
The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: results of a randomized trial.
Topics: Blood Pressure; Carotid Arteries; Diabetes Mellitus, Type 2; Diuretics; Dose-Response Relationship, | 2014 |
Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mell | 2015 |
Treatment of Hypertensive Patients With Diabetes and Microalbuminuria With Combination Indapamide SR/Amlodipine: Retrospective Analysis of NESTOR.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Ca | 2015 |
[Possibilities of Correction of Endothelial Dysfunction at the Background of Combined Antihypertensive Therapy in Patients With Arterial Hypertension and Type 2 Diabetes].
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Diabetes Mellitus, Type 2; Dos | 2015 |
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Combin | 2016 |
Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Endpoint Determination; Female; F | 2016 |
Absence of Peripheral Pulses and Risk of Major Vascular Outcomes in Patients With Type 2 Diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diagnostic Techniques, Cardiovascular; Disea | 2016 |
Lowering of brachial pulse pressure in 9379 hypertensives with type 2 diabetes and reduction of cardiovascular events.
Topics: Antihypertensive Agents; Blood Pressure; Brachial Artery; Cardiovascular Diseases; Cohort Studies; D | 2008 |
Blood pressure lowering with fixed combination perindopril-indapamide: key findings from ADVANCE.
Topics: Aged; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Combinations; Female; | 2008 |
Lowering blood pressure reduces renal events in type 2 diabetes.
Topics: Age of Onset; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2009 |
[Combined antihypertensive treatment of patients with hypertension and type 2 diabetes mellitus].
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Carbohydrate Metabolism; Diabet | 2009 |
[Hypotensive and metabolic effect of indapamide and perindopril in patients with type 2 diabetes and arterial hypertensia].
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Indapamide; Male; | 2009 |
[Immunomodulating, metabolic and cardioprotective effects of AT1-angiotensin receptors blocker losartan in patients with coronary heart disease and type 2 diabetes mellitus].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiotonic Agents; C | 2009 |
Treating hypertension by rational use of diuretics: results of the Russian ARGUS-2 Study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Delayed-Action Preparations | 2009 |
Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Re | 2009 |
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; | 2009 |
[Combined antihypertensive therapy in patients with arterial hypertension and type 2 diabetes].
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Diabetes Melli | 2009 |
The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; D | 2010 |
Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2010 |
Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combinatio | 2010 |
Management of high blood pressure in type 2 diabetes: perindopril/indapamide fixed-dose combination and the ADVANCE trial [corrected].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type 2; Diuretics | 2010 |
Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Delayed-A | 2010 |
Contemporary model for cardiovascular risk prediction in people with type 2 diabetes.
Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Asia; Australasia; Blood Glucose; Canad | 2011 |
Effects of perindopril-indapamide on left ventricular diastolic function and mass in patients with type 2 diabetes: the ADVANCE Echocardiography Substudy.
Topics: Aged; Diabetes Mellitus, Type 2; Diastole; Electrocardiography; Female; Heart Ventricles; Humans; In | 2011 |
[Lowering blood pressure and glucose reduces renal events in type 2 diabetes; ADVANCE study].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Diabetic Nephropathies; D | 2010 |
Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial.
Topics: Aged; Asia; Australia; Blood Glucose; Canada; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Euro | 2011 |
Effects of blood pressure lowering on cardiovascular outcomes in different cardiovascular risk groups among participants with type 2 diabetes.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; D | 2012 |
[Management of hypertensive patients with left ventricular hypertrophy].
Topics: Adrenergic alpha-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 2002 |
[Treatment of hypertensive type 2 diabetes patients with microalbuminuria].
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Creatinine; Data Int | 2002 |
Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Blood Pressure; Cough; Diabetes Mellitus, Type 2; | 2003 |
[ADVANCE study: objectives, design and current status].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood Press | 2003 |
Effect of indapamide SR on microalbuminuria--the NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia)--rationale and protocol for the main trial.
Topics: Adult; Aged; Albuminuria; Clinical Protocols; Creatine; Delayed-Action Preparations; Diabetes Mellit | 2003 |
Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Delayed-Action Preparations; Diabetes | 2003 |
Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cross-Over Studie | 2003 |
Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Doubl | 2004 |
ADVANCE: breaking new ground in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type 2; Diuretics | 2006 |
Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes.
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Enalapril; Female; Humans; Hy | 2007 |
ADVANCE: lessons from the run-in phase of a large study in type 2 diabetes.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Me | 2006 |
Circadian blood pressure variation and antihypertensive medication adjustment in normoalbuminuric type 2 diabetes patients.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Circadian Rhythm; Diab | 2007 |
Vascular outcome in type 2 diabetes: an ADVANCE?
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type 2; Diuretics; Drug | 2007 |
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Me | 2007 |
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Me | 2007 |
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Me | 2007 |
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Me | 2007 |
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Me | 2007 |
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Me | 2007 |
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Me | 2007 |
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Me | 2007 |
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Me | 2007 |
[Clinical trial of the month. ADVANCE: improved survival and better vascular and renal outcomes with a fixed combination of perindopril and indapamide in patients with type 2 diabetes].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiovascular Diseases; Di | 2007 |
[ADVANCE: a morbidity mortality study of diabetes and hypertension].
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; | 2008 |
Regression of microalbuminuria: results of a controlled study, indapamide versus captopril.
Topics: Aged; Albuminuria; Analysis of Variance; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; Femal | 1993 |
Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM.
Topics: Albuminuria; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Blood P | 1995 |
Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Clinical Protocols; Diabetes Mellitus, Type 2; Diabe | 2001 |
32 other studies available for indapamide and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
How to treat arterial hypertension in obese patients?
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Diuretics; Humans; Hypertension; Indapamide; Obe | 2020 |
Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Fem | 2017 |
Utility of fixed-dose single tablet antihypertensive drug combinations in Cameroonians with type 2 diabetes and newly diagnosed hypertension.
Topics: Africa South of the Sahara; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, | 2019 |
Prevalence of hyponatremia among patients who used indapamide and hydrochlorothiazide: a single center retrospective study.
Topics: Adolescent; Age Factors; Aged; Aged, 80 and over; Biomarkers; Chi-Square Distribution; Comorbidity; | 2013 |
[Cardiorenal continuum. Nephro- and cardioprotection with perindopril/indapamide therapy].
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cardio-Renal Syndrome; Cause of Death; Cli | 2013 |
Evidence-based triple antihypertensive therapy yields lower mortality in older patients with diabetes mellitus.
Topics: Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Combinations; Female; Gl | 2014 |
Efficacy and tolerability of fixed-dose combination of perindopril/indapamide in type 2 diabetes mellitus: PICASSO trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Dru | 2014 |
Natriuresis and blood pressure reduction in hypertensive patients with diabetes mellitus: the NESTOR study.
Topics: Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Enalapril | 2015 |
Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score.
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2016 |
[The Results of Long-Term Observation of Patients Who Participated in the ADVANCE Trial].
Topics: Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Human | 2015 |
Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combinations | 2016 |
Full-dose Perindopril/Indapamide in the Treatment of Difficult-to-Control Hypertension: The FORTISSIMO Study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diuretics; Drug Combinatio | 2017 |
Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: an analysis of the PROGRESS and ADVANCE trials.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Drug Combinations; Female; | 2017 |
Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Complications; Diabetes Melli | 2009 |
Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
Topics: Aged; Antihypertensive Agents; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Diabetic A | 2009 |
[Nephroprotection diabetes mellitus type 2: lessons from the ADVANCE trial].
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combinatio | 2011 |
[The challenge to treat hypertensive patients with type 2 diabetes].
Topics: Adult; Albuminuria; Antihypertensive Agents; Body Mass Index; Cardiovascular Diseases; Diabetes Mell | 2002 |
[Reflexion of French experts on the key points of the symposium].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
Cardiovascular protective role of a low-dose antihypertensive combination in obese Zucker rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Cardiova | 2003 |
What can be learned from the experience with the fixed low-dose combination of perindopril/indapamide in the treatment of hypertension?
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, T | 2005 |
[Type 2 diabetes: blood pressure lowering to 135/75 mmHg reduces mortality].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Diabetes Mellitus, Type 2; Diuretics | 2007 |
Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial.
Topics: Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Human | 2007 |
The ADVANCE trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Clinical Trials as Topic; Diabetes Mellitu | 2008 |
Advances in reducing the burden of vascular disease in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type | 2008 |
Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Diabete | 2008 |
[Results of ADVANCE trial conducted in type 2 diabetic patients].
Topics: Cardiovascular Diseases; Congresses as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Europe; | 2008 |
[Type 2 diabetes. Routine ACE inhibitors?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug C | 2008 |
Blood pressure and diabetic control. Results of indapamide treatment.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; Female; Humans; Hypertension; Inda | 1984 |
Indapamide-induced severe hyponatremia and hypokalemia.
Topics: Diabetes Mellitus, Type 2; Diagnosis, Differential; Diuretics; Female; Humans; Hypokalemia; Hyponatr | 1995 |
Regression of microalbuminuria in type II diabetic, hypertensive patients after long-term indapamide treatment.
Topics: Adult; Albuminuria; Blood Pressure; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Humans; H | 1991 |
Antihypertensive therapy in diabetic patients. The use of indapamide.
Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diuretics; Drug Evaluation; Glucose Tolera | 1988 |
Efficacy and safety of medium term indapamide treatment in hypertensive diabetic patients.
Topics: Adult; Diabetes Mellitus, Type 2; Diuretics; Female; Humans; Hypertension; Indapamide; Male; Middle | 1985 |